StockNews.com Upgrades Sanofi (NASDAQ:SNY) to “Strong-Buy”

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a report issued on Friday morning.

Separately, Argus boosted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $57.50.

Sanofi Stock Performance

Shares of SNY stock opened at $52.09 on Friday. Sanofi has a 12-month low of $42.63 and a 12-month high of $55.72. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $131.93 billion, a price-to-earnings ratio of 26.18, a price-to-earnings-growth ratio of 1.63 and a beta of 0.59. The business has a 50 day simple moving average of $49.29 and a 200 day simple moving average of $48.66.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same quarter in the prior year, the business posted $0.95 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, equities research analysts anticipate that Sanofi will post 4.14 EPS for the current year.

Institutional Investors Weigh In On Sanofi

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its stake in shares of Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Mondrian Investment Partners LTD grew its position in Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after buying an additional 1,190,141 shares during the last quarter. Armistice Capital LLC bought a new position in shares of Sanofi in the fourth quarter valued at $51,520,000. BNP Paribas Financial Markets lifted its position in shares of Sanofi by 3,440.6% during the 1st quarter. BNP Paribas Financial Markets now owns 1,033,549 shares of the company’s stock valued at $50,230,000 after acquiring an additional 1,004,358 shares during the last quarter. Finally, Morningstar Investment Services LLC raised its position in shares of Sanofi by 99.5% during the fourth quarter. Morningstar Investment Services LLC now owns 1,486,949 shares of the company’s stock worth $73,425,000 after purchasing an additional 741,456 shares during the period. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.